Pfizer executive committee (correction)
Executive Summary
Senior VP-Corporate Affairs Chuck Hardwick will retire following the creation of the company's new executive committee, while Senior VP-Human Resources Yvonne Jackson is leaving the company. "The Pink Sheet" incorrectly switched their departure descriptions (1"The Pink Sheet" Feb. 28, 2005, p. 20)...
You may also be interested in...
Pfizer Streamlines Upper Management; Katen Positioned As Heir Apparent
Pfizer's newly created corporate executive committee streamlines the company's top management structure
EU Experts Want One-Stop-Shop EU Governance That Mimics Best Of Other Jurisdictions
It may be blue sky thinking to surmise how a new EU medtech regulatory governance structure could evolve. But with change on the horizon, experts see exciting opportunities.
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.